PFBT
DNLI icon

Parkside Financial Bank & Trust’s Denali Therapeutics DNLI Stock Holding History

Parkside Financial Bank & Trust’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.63K Hold
189
– – ﹤0.01% 1920
2025
Q4 		$3.12K Hold
189
– – ﹤0.01% 1953
2025
Q3 		$2.75K Buy
189
+39
+26% +$560 ﹤0.01% 1909
2025
Q2 		$2.1K Buy
+150
New +$2.11K ﹤0.01% 1986

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parkside Financial Bank & Trust's DNLI Position: Q1 2026 in Review

Parkside Financial Bank & Trust held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 189 shares worth $3.63K. The position accounts for ﹤0.01% of the portfolio, ranked #1920.

Parkside Financial Bank & Trust first reported a position in DNLI in Q2 2025 and has held it in 4 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Parkside Financial Bank & Trust held 189 shares of Denali Therapeutics worth $3.63K as of Q1 2026.
  • Parkside Financial Bank & Trust left its Denali Therapeutics share count unchanged in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #1920 holding.
  • Parkside Financial Bank & Trust first reported a position in Denali Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.